NIDA National Early Warning System Network (iN3): An Innovative Approach

描述：本合作协议申请旨在减轻美国药物滥用的负担。目前，对新出现的药物使用做法的了解来自缺乏临床准确性的零星病例报告，以及报告时间滞后的现有监测系统。我们将加快对新出现的药物滥用趋势的反应，通过建立iN3，一个创新的NIDA国家早期预警系统网络，它将迅速识别、评估和传播有关新出现的药物使用模式的信息。iN3将协调多个数据流，以发现新出现的精神活性药物使用模式和不良影响。iN3的核心是它的科学咨询小组（SAG）。成员们将评估两种协同数据流，以确定新出现的药物使用模式。第一个数据流将来自毒理学调查协会（“ToxIC”），这是一个由美国国立卫生研究院支持的医学毒理学家组成的网络，专门从事识别和确认涉及精神活性物质的前哨事件。毒性研究人员位于美国17个哨点。SAG与NIDA合作，将分析毒性研究人员对新出现药物使用的急性、亚急性和慢性影响患者的访谈报告。第二项涉及来自社交媒体（Twitter feed）、Erowid（一个精神百科全书）和Bluelight（一个吸毒网络论坛）的药物使用测量。我们将利用我们在NIH拨款R21DA30571 （PREDOSE）中开发的创新信息处理方法来增强这些数据流之间的协同作用，以分析Twitter、Erowid和Bluelight上的新内容，以确定新出现的药物使用趋势，以及潜在的地理位置。来自半自动化内容分析的数据将在毒性调查人员之间传播，以确定与新出现的精神活性药物使用有关的模式。相反，来自毒性研究人员床边访谈的信息将提高PREDOSE+平台的分析精度。来自这些数据流的信息将由协调中心（HCC）整合，以供SAG审查。SAG将通过交互式网站、列表服务和会议等快速通信方式传播调查结果。我们的跨学科团队在美国国立卫生研究院资助的药物流行病学和新兴药物使用趋势方面拥有丰富的经验。本提案的具体目标是：1)在多个社区一级指标中确定新出现的药物使用事件；2)传播新发用药的发生、特征、临床及不良反应等信息。创新：将社交媒体数据源与床边临床检查相关联是高度创新的。意义：通过将先进的内容分析整合到现有的临床哨点网络中，iN3有能力将药物监测领域从反应性科学推进到预见性科学。影响：iN3将产生公共卫生影响，因为它提供了一种工具，可以为截断和预防新出现的药物使用疫情的努力提供信息。

DESCRIPTION: This Cooperative Agreement application is designed to decrease the burden of substance abuse in the United States. Currently, knowledge of emerging drug use practices is derived from sporadic case reports that lack clinical accuracy, and existing surveillance systems that lag in reporting time. We will accelerate the response to emerging drug abuse trends by establishing iN3, an innovative NIDA National Early Warning System Network that will rapidly identify, evaluate, and disseminate information on emerging drug use patterns. The iN3 will harmonize multiple data streams to detect emerging patterns of psychoactive drug use and adverse effects. At the heart of iN3 is its Scientific Advisory Group (SAG). Members will assess two synergistic data streams to identify emerging patterns of drug use. The first data stream will be derived from the Toxicology Investigators Consortium ("ToxIC"), an NIH-supported network of medical toxicologists who specialize in recognizing and confirming sentinel events involving psychoactive substances. ToxIC investigators are located at 17 sentinel sites across the U.S. The SAG, in collaboration with NIDA, will analyze reports from ToxIC investigators' interviews of patients with acute, subacute, and chronic effects of emerging drug use. The second involves measures of drug use derived from social media (Twitter feeds), Erowid (a psychoactive encyclopedia), and Bluelight (a drug use web forum). We will enhance the synergy between these data streams by leveraging our innovative information processing approach developed in NIH grant R21DA30571 (PREDOSE), to analyze new content on Twitter, Erowid, and Bluelight to identify emerging drug use trends, and, potentially, geolocations. Data from semi-automated content analysis will be disseminated among ToxIC investigators to identify patterns related to emerging psychoactive drug use. Conversely, information from ToxIC investigators' bedside interviews will improve the analytical precision of the PREDOSE+ platform. Information from these data streams will be integrated by the Harmonized Coordinating Center (HCC) for SAG review. The SAG will disseminate findings via rapid communications such as interactive websites, listservs, and conferences. Our interdisciplinary team has extensive experience in NIH-funded drug epidemiology and emerging drug use trends. The Specific Aims of this proposal are to: 1) Identify new episodes of emerging drug use in multiple community-level indicators; and 2) Disseminate information about occurrence, identity, clinical, and adverse effects of emerging drug use. Innovation: Correlating social media data sources with bedside clinical examinations is highly innovative. Significance: By integrating advanced content analysis into an existing clinical network of sentinel sites, iN3 has the capacity to advance the field of drug surveillance from a reactive to anticipatory science. Impact: iN3 will have a public health impact by providing a tool that can inform efforts to truncate and prevent outbreaks of emerging drug use.